MetaCap

Iambic Therapeutics (IAM) News

NASDAQ: IAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

13.11-1.15 (-8.06%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IAM news summary

We found 6 recent headlines mentioning Iambic Therapeutics (IAM): 3 in the past week and 5 in the past 30 days, most often from GlobeNewswire, Nasdaq, Seeking Alpha. IAM is making an outsized move today, down 8.06% at $13.11, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium", was published by GlobeNewswire on Nov 18, 2026.

Headlines link to the original publishers. MetaCap does not republish third-party articles.

Summary generated from market data by MetaCap's automated system. Methodology

Latest Iambic Therapeutics headlines

Stocks mentioned alongside IAM

Compare IAM